» Articles » PMID: 31672446

Circulating Levels of Gastrointestinal Hormones in Response to the Most Common Types of Bariatric Surgery and Predictive Value for Weight Loss over One Year: Evidence from Two Independent Trials

Overview
Journal Metabolism
Specialty Endocrinology
Date 2019 Nov 2
PMID 31672446
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Bariatric surgery leads to profound and sustainable weight loss. Gastrointestinal hormones are involved in energy and glucose homeostasis, thus postoperative changes of their circulating levels may be mediating future weight loss. To investigate how the circulating concentrations of gastrointestinal hormones change in response to the most common types of bariatric operation and whether these changes can predict future weight loss.

Materials And Methods: We measured circulating GLP-1, GLP-2, oxyntomodulin, glicentin, glucagon, major proglucagon fragment (MPGF), ghrelin, GIP, PYY after overnight fasting and/or after a mixed meal test (MMT) in: a) 14 subjects that have undergone either an adjustable gastric banding [AGB] (n = 9) or a Roux-en-Y bypass (RYGB) (n = 5) (Pilot study 1), b) 28 subjects that have undergone either a vertical sleeve gastrectomy (n = 17) or a RYGB (n = 11) before and three, six and twelve months after surgery.

Results: In addition to the expected associations with GLP-1, the most robust increases were observed in postprandial levels of oxyntomodulin and glicentin three months after VSG or RYGB (but not after AGB) and are associated with degree of weight loss. Oxyntomodulin and glicentin levels at the third and sixth month postoperative visit are positively associated with feeling of satiety which may be underlying the observed associations with future weight loss.

Conclusion: Beyond GLP-1, early postprandial changes in circulating oxyntomodulin and glicentin are predictors of weight loss after bariatric surgery, possibly through regulation of satiety. Further studies should focus on underlying mechanisms, and their potential as attractive therapeutic tools against obesity and related comorbidities.

Citing Articles

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk.

Valdecantos M, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M Nat Commun. 2024; 15(1):10342.

PMID: 39609390 PMC: 11605122. DOI: 10.1038/s41467-024-54080-w.


Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.

Kokkinos A, Tsilingiris D, Simati S, Stefanakis K, Angelidi A, Tentolouris N Metabolism. 2024; 152:155773.

PMID: 38181882 PMC: 10872266. DOI: 10.1016/j.metabol.2023.155773.


Suboptimal Weight Loss 13 Years After Roux-en-Y Gastric Bypass Is Associated with Blunted Appetite Response.

Nymo S, Lundanes J, Eriksen K, Aukan M, Rehfeld J, Holst J Obes Surg. 2023; 34(2):592-601.

PMID: 38159146 PMC: 10811108. DOI: 10.1007/s11695-023-07028-w.


Significance of Hormone Alteration Following Bariatric Surgery.

Slouha E, Elkersh E, Shay A, Ghosh S, Mahmood A, Gorantla V Cureus. 2023; 15(11):e49053.

PMID: 38116338 PMC: 10729911. DOI: 10.7759/cureus.49053.


Bariatric Surgery and Gut-Brain-Axis Driven Alterations in Cognition and Inflammation.

Custers E, Franco A, Kiliaan A J Inflamm Res. 2023; 16:5495-5514.

PMID: 38026245 PMC: 10676679. DOI: 10.2147/JIR.S437156.